预约演示
更新于：2025-10-25
Cagrilintide
更新于：2025-10-25
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 720102737
来源: *****
关联
36
项与 Cagrilintide 相关的临床试验NCT07220759
Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.
开始日期2025-11-05 |
申办/合作机构 |
NCT07220642
Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity
This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.
开始日期2025-11-05 |
申办/合作机构 |
NCT07010432
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism During Weight Loss in Postmenopausal Women With Obesity
In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and semaglutide. The purpose is to examine whether cagrilintide can reduce the decline in bone mass associated to weight loss. Participants will either get cagrilintide, semaglutide, CagriSema (cagrilintide combined with semaglutide), or placebo. Which treatment participants get is decided by chance. Semaglutide is already approved for the treatment of overweight and obesity and can be prescribed by doctors. Cagrilintide and CagriSema are new medications currently under development for weight management. The study will last for about 79 weeks.
开始日期2025-06-12 |
申办/合作机构 |
100 项与 Cagrilintide 相关的临床结果
登录后查看更多信息
100 项与 Cagrilintide 相关的转化医学
登录后查看更多信息
100 项与 Cagrilintide 相关的专利（医药）
登录后查看更多信息
68
项与 Cagrilintide 相关的文献（医药）2025-11-01·CURRENT DRUG TARGETS
A Review of Amylin Peptide Receptor Activators for Obesity
Pharmacotherapy
Article
作者: Lee, Sangmin
Amylin is a thirty-seven amino acid peptide hormone that is secreted from the pancreas
with insulin. The peptide hormone amylin activates its receptors in the brain to regulate blood glucose
and food appetite. Interestingly, the amylin receptor is the heterodimer of the calcitonin receptor
(which is the receptor for the peptide hormone calcitonin) and an accessory protein called receptor
activity-modifying protein. Amylin receptor activation has emerged as a promising drug target
for the treatment of diabetes and obesity. Recent pharmaceutical efforts with amylin receptor
activators have focused on developing drugs for the treatment of obesity. Multiple amylin analogs
have been tested in pre-clinical settings, and some are currently being tested in clinical trials. For
this review, recent research publications and available information regarding drug development
targeting amylin receptors were collected. This review summarizes the amylin receptor activators
currently being tested in clinical trials for the treatment of obesity. In addition, recent research
achievements were demonstrated, such as the introduction of mutations that enhanced receptor
affinity/potency and the development of a method for measuring selective amylin receptor activation.
Potential issues along with peptide drug development were described, including lipidation to
achieve a long-acting property. The combination of an amylin analog and other anti-obesity peptide
drugs has demonstrated higher clinical efficacy in reducing body weight than monotherapy.
The combination therapy is likely to be the first drug therapy where an amylin analog is used for
obesity treatment. In addition, amylin receptor activators may have an adverse effect profile more
favorable than that of GLP-1 receptor activators, which could be a potential benefit of amylin receptor
activators.
2025-11-01·MEDICINA CLINICA
Weight management treatment in obesity
Review
作者: Rubio-Herrera, Miguel A ; Mera-Carreiro, Sara
Obesity is a chronic and relapsing disease associated with medical complications and mortality. Our improved understanding of the relevance of the gut-brain axis in regulating appetite and body weight has encouraged research into nutrient-stimulated gastroenteropancreatic hormones as a new therapeutic arsenal for the treatment of people living with obesity. Beyond the necessary lifestyle changes, this new era with second-generation drugs has been able to achieve weight loss of 15-25%, close to that of bariatric surgery. Glucagon-like peptide-1 (GLP-1) receptor agonists (RA), used as weekly injectable monotherapy or daily oral (semaglutide), achieve weight loss of 15-17%, with a good safety profile. The synergistic combination with other hormones (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, or amylin) will allow to increase weight loss, as well as improve cardiometabolic variables. Tirzepatide (a dual GLP-1/GIP receptor agonist) achieves weight loss of up to 22.5% at the highest doses. In this same range of weight loss, it is expected that it can be achieved with the combination of Cagrisema (cagrilintide 2.4mg plus semaglutide 2.4mg), combinations of GLP-1 RAs - glucagon agonists or with the triple combination of GLP-1 RAs-GIP-Glucagon (Retatrutide). In this review, we will examine the efficacy and safety of the drugs marketed and others under ongoing clinical trials for the treatment of persons with obesity, as well as the main challenges faced by both healthcare professionals and patients in maintaining long-term treatment.
2025-10-01·Molecular Metabolism
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Article
作者: Tidemann-Miller, Beth ; San Tham, Lai ; He, Minxia Michelle ; Lansu, Katherine ; Allen, Dawn ; Pratt, Edward ; Qu, Hongchang ; Coskun, Tamer ; Long, Annie ; Bhattachar, Shobha N ; Bowen, Breanna ; Ibriga, Hilda ; Mather, Kieren J ; O'Farrell, Libbey ; Moyers, Julie S ; Haupt, Axel ; Briere, Daniel A ; Alsina-Fernandez, Jorge
OBJECTIVE:
Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity.
METHODS:
In vitro assays were performed in cell lines selectively expressing rat or human amylin 1 receptor (AMY1R), amylin 3 receptor (AMY3R), or calcitonin receptor (CTR). In vivo studies were conducted in rats and monkeys. A phase 1, randomized, placebo-controlled, participant/investigator-blinded trial evaluated the safety and tolerability of single-ascending eloralintide doses (0.04-12 mg) in healthy participants (NCT05295940).
RESULTS:
In vitro, eloralintide preferentially activated human AMY1R (12-fold > CTR, 11-fold > AMY3R), while in rats, both AMY1R and AMY3R were activated more potently than CTR. Eloralintide induced significantly less conditioned taste avoidance in lean rats than cagrilintide, a non-selective amylin receptor agonist (p<0.05). Eloralintide dose dependently reduced food intake and lowered body weight, primarily through fat mass loss, in diet-induced obese rats. Eloralintide demonstrated favorable pharmacokinetics in both rats and monkeys. In the phase 1 trial, 48 healthy participants had a mean body mass index of 27.5 kg/m2. Nine participants in the eloralintide cohorts reported 16 adverse events, with most being mild (n=15/16). Two participants reported 4 gastrointestinal events, including one moderate vomiting event. The pharmacokinetic profile of eloralintide supports once-weekly dosing. In eloralintide cohorts receiving single doses of 4 or 12 mg, week-4 mean percent change from baseline in body weight was -2.5% (p<0.01) and -4.4% (p<0.001), respectively, vs placebo (+0.6%). (+0.6%).
CONCLUSION:
Once-weekly dosing with eloralintide, an AMY1R-selective agonist, may offer a promising new therapeutic with favorable gastrointestinal tolerability for the treatment of obesity.
198
项与 Cagrilintide 相关的新闻（医药）2025-10-23
N Engl J Med[Jour] AND 393[volume] AND 1[issue]
新英格兰医学杂志 393卷1期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Corporatization of U.S. Health Care: Defining Health Care “Corporatization”
美国医疗保健的企业化：界定医疗保健“企业化”
E.C. Fuse Brown
N Engl J Med; July 3, 2025; 393(1)：1-3
2
Self-Neglect in Older People — A Clinical, Social, and Ethical Dilemma
老年人自我忽视——临床、社会和伦理困境
K. Lees Haggerty and D.B. Reuben
N Engl J Med; July 3, 2025; 393(1)：4-6
3
Biologic Drugs and Medicare Price Negotiation
生物制剂与医保价格谈判
T.J. Hwang , N.L. Keating , and S.B. Dusetzina
N Engl J Med; July 3, 2025; 393(1)：6-9
4
The Autopsy Report
尸检报告
K. Klara
N Engl J Med; July 3, 2025; 393(1)：9-11
ORIGINAL ARTICLES（论著）
5
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
结肠癌辅助化疗后的结构化运动
K.S. Courneya and Others
N Engl J Med; July 3, 2025; 393(1)：13-25
6
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
与司美格鲁肽相比，替西帕肽治疗肥胖症的效果
L.J. Aronne and Others
N Engl J Med; July 3, 2025; 393(1)：26-36
7
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
局部晚期头颈癌的新型辅助和辅助帕博利珠单抗治疗
R. Uppaluri and Others
N Engl J Med; July 3, 2025; 393(1)：37-50
8
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
奥贝胆酸在心血管高危患者中的安全性和有效性
S.J. Nicholls and Others
N Engl J Med; July 3, 2025; 393(1)：51-61
REVIEW ARTICLE（综述）
9
Forensic Pathology
法医病理学
R.D. Folkerth , B.A. Sampson , and J.K. Graham
N Engl J Med; July 3, 2025; 393(1)：62-71
IMAGES IN CLINICAL MEDICINE（临床医学影像）
10
Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis
抗中性粒细胞胞浆抗体相关性血管炎导致的弥漫性肺泡出血
I.S. Lee
N Engl J Med; July 3, 2025; 393(1)：72
11
Frostbite Injury from Inhaled Nitrous Oxide Use
吸入一氧化二氮导致的冻伤损伤
M. Patrizio and M. Hayden
N Engl J Med; July 3, 2025; 393(1)：e1
CLINICAL PROBLEM-SOLVING（临床问题解决）
12
Caving In to Pressure
屈服于压力
S.I. Gomez-Villegas and Others
N Engl J Med; July 3, 2025; 393(1)：73-79
EDITORIALS（社论）
13
The Corporatization of U.S. Health Care — A New Perspective Series
美国医疗保健的企业化——一个新的观点与视角系列
D. Malina and Others
N Engl J Med; July 3, 2025; 393(1)：81-82
14
Extending Cancer Survival with Exercise — Time for Oncology to Act
通过运动延长癌症患者生存期——肿瘤学该行动了
M.L. Irwin
N Engl J Med; July 3, 2025; 393(1)：82-84
15
Semaglutide and Tirzepatide to Treat Obesity
司美格鲁肽和替西帕肽治疗肥胖症
F.L. Greenway
N Engl J Med; July 3, 2025; 393(1)：84-85
16
Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer
在头颈癌根治性治疗中运用免疫疗法
A.J. Rosenberg and E.E. Vokes
N Engl J Med; July 3, 2025; 393(1)：85-87
SOUNDING BOARD（议事堂）
17
From the National Academy of Medicine: Climate Change and Human Health — A Research Agenda for Action
来自美国国家医学院的观点：气候变化与人类健康——行动研究议程
V.J. Dzau and Others
N Engl J Med; July 3, 2025; 393(1)：88-92
CORRESPONDENCE（读者来信）
18
Lifesaving Diagnosis through Prenatal Genomic Sequencing
通过产前基因组测序作出挽救生命的诊断
N Engl J Med; July 3, 2025; 393(1)：93-95
19
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
2型糖尿病患者强化血压控制
N Engl J Med; July 3, 2025; 393(1)：95-98
20
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections
血流感染患者抗生素治疗7天与14天的对比
N Engl J Med; July 3, 2025; 393(1)：98-101
21
Dapagliflozin in Patients Undergoing TAVI
接受经导管主动脉瓣植入术患者使用达格列净的情况
N Engl J Med; July 3, 2025; 393(1)：101-103
22
Further Comments on Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy
关于利司扑兰用于脊髓性肌萎缩症产前治疗的进一步评论
N Engl J Med; July 3, 2025; 393(1)：103-104
N Engl J Med[Jour] AND 393[volume] AND 2[issue]
新英格兰医学杂志 393卷2期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Who Will Care for America? Immigration Policy and the Coming Health Workforce Crisis
谁来关照美国？移民政策与即将到来的医疗劳动力危机
P.M.G. Santos , R. Jagsi , and C.I.A. Oronce
N Engl J Med; July 10, 2025; 393(2)：105-107
2
Exclusion of Elective Care from Hospital Financial Assistance Policies — Arresting a Troubling Development
医院财务援助政策中排除择期护理——遏制令人不安的发展态势
M.A. Hall and J. Garber
N Engl J Med; July 10, 2025; 393(2)：107-110
3
Libraries Burned, a Life Lived
图书馆被焚，人生如旅
T. Vijayan
N Engl J Med; July 10, 2025; 393(2)：110-111
ORIGINAL ARTICLES（论著）
4
As-Needed Albuterol–Budesonide in Mild Asthma
按需使用沙丁胺醇-布地奈德治疗轻度哮喘
C. LaForce and Others
N Engl J Med; July 10, 2025; 393(2)：113-124
5
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates
心血管危险因素对终生风险的全球影响
The Global Cardiovascular Risk Consortium
N Engl J Med; July 10, 2025; 393(2)：125-138
6
Intravenous Tenecteplase before Thrombectomy in Stroke
卒中血栓切除术前静脉注射替奈普酶
Z. Qiu and Others
N Engl J Med; July 10, 2025; 393(2)：139-150
7
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer
Inavolisib治疗PIK3CA突变型晚期乳腺癌的总生存期
K.L. Jhaveri and Others
N Engl J Med; July 10, 2025; 393(2)：151-161
REVIEW ARTICLE（综述）
8
Juvenile Idiopathic Arthritis
幼年特发性关节炎
C.I. Sandborg , G.S. Schulert , and Y. Kimura
N Engl J Med; July 10, 2025; 393(2)：162-174
IMAGES IN CLINICAL MEDICINE（临床医学影像）
9
Whipple’s Disease with Endocarditis
伴有心内膜炎的惠普尔病
P. Ackermann and M.A. Borger
N Engl J Med; July 10, 2025; 393(2)：175
10
Incarcerated Femoral Hernia
嵌顿性股疝
P. Rana and H. Jivani
N Engl J Med; July 10, 2025; 393(2)：e2
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
11
Case 19-2025: A 69-Year-Old Man with Headache and Ataxia
病例19-2025：一名69岁男性，头痛且共济失调
A. Venkatesan and Others
N Engl J Med; July 10, 2025; 393(2)：176-184
EDITORIALS（社论）
12
Your Combination Asthma Inhaler — Don’t Leave Home without It!
你的联合哮喘吸入器——出门别忘了带！
J.M. Drazen
N Engl J Med; July 10, 2025; 393(2)：186-187
13
Estimates of Cardiovascular Risks and Benefits — When Knowing Is Not Enough
心血管风险和获益的评估——光知晓并不够
G.A. Mensah
N Engl J Med; July 10, 2025; 393(2)：187-189
14
Thrombolysis before Thrombectomy in Stroke — A Bridge Not Fallen
卒中血栓切除术前溶栓治疗——一座未坍塌的桥梁
T.W. Leung
N Engl J Med; July 10, 2025; 393(2)：189-191
SOUNDING BOARD（议事堂）
15
From the National Academy of Medicine: Transforming Health Care — Shared Commitments for a Learning Health System
来自美国国家医学院的观点：转变医疗保健模式——构建学习型医疗系统的共同承诺
J.L. Madara and Others
N Engl J Med; July 10, 2025; 393(2)：192-197
CORRESPONDENCE（通信）
16
Expansion of tetM-Carrying Neisseria gonorrhoeae in the United States, 2018–2024
2018-2024年美国携带tetM的淋病奈瑟菌的扩散情况
N Engl J Med; July 10, 2025; 393(2)：198-200
17
Atrial Appendage Closure after Ablation for Atrial Fibrillation
心房颤动消融术后左心耳封堵
N Engl J Med; July 10, 2025; 393(2)：200-203
18
Tumor-Infiltrating Clonal Hematopoiesis
肿瘤浸润性克隆性造血
N Engl J Med; July 10, 2025; 393(2)：203-205
19
Wealth and Mortality in the United States and Europe
美国和欧洲的财富与死亡率
N Engl J Med; July 10, 2025; 393(2)：205-207
20
Addressing Alcohol Use
应对酒精使用问题
N Engl J Med; July 10, 2025; 393(2)：207-208
N Engl J Med[Jour] AND 393[volume] AND 3[issue]
新英格兰医学杂志 393卷3期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Role of Public Health Agencies in Creating Vaccine Policy
公共卫生机构在制定疫苗政策中的作用
P. Marks
N Engl J Med; July 17, 2025; 393(3):209-211
2
New Mammography Tools — The Need for Clinically Meaningful Assessment Standards
新的乳腺钼靶工具——需要有临床意义的评估标准
B. Hyams , K. Kerlikowske , and R.F. Redberg
N Engl J Med; July 17, 2025; 393(3):211-213
3
The Second Life of Jacqui B.
Jacqui B.的第二人生。
M. Earnest and P. Khazanie
N Engl J Med; July 17, 2025; 393(3):214-215
ORIGINAL ARTICLES（论著）
4
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
杜伐鲁单抗在胃和胃食管结癌围手术期的应用
Y.Y. Janjigian and Others
N Engl J Med; July 17, 2025; 393(3):217-230
5
First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate
强的松或甲氨蝶呤治疗肺结节病的一线治疗
V. Kahlmann and Others
N Engl J Med; July 17, 2025; 393(3):231-242
6
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
环磷酰胺和环孢素预防移植物抗宿主病
D.J. Curtis and Others
N Engl J Med; July 17, 2025; 393(3):243-254
7
Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis
小儿肠胃炎急诊后多剂量昂丹司琼的疗效
S.B. Freedman and Others
N Engl J Med; July 17, 2025; 393(3):255-266
8
Brief Report: Rapid Recovery of Donor Hearts for Transplantation after Circulatory Death
简要报告：供体心脏在循环性死亡后快速恢复
A.M. Williams and Others
N Engl J Med; July 17, 2025; 393(3):267-274
9
Brief Report: On-Table Reanimation of a Pediatric Heart from Donation after Circulatory Death
简要报告：一名循环死亡后捐赠的儿童心脏在手术台上复活
J.A. Kucera , D.M. Overbey , and J.W. Turek
N Engl J Med; July 17, 2025; 393(3):275-280
REVIEW ARTICLE(综述)
10
The Spectrum of Fragile X Disorders
脆性X染色体紊乱谱系
R.J. Hagerman and P.J. Hagerman
N Engl J Med; July 17, 2025; 393(3):281-288
IMAGES IN CLINICAL MEDICINE（临床医学影像学）
11
Acrometastases
Acrometastases
H. O’Rourke and M. Iddawela
N Engl J Med; July 17, 2025; 393(3):289
12
Microcysts in Lithium-Induced Nephropathy
锂诱发肾病中的微囊
C.-H. Liao and K.-L. Liu
N Engl J Med; July 17, 2025; 393(3):e3
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马赛诸塞州总医院病例记录）
13
Case 20-2025: An 86-Year-Old Woman with Neck Swelling and Dysphagia
病例20-2025:86岁女性，颈部肿胀和吞咽困难
M.L. Russell and Others
N Engl J Med; July 17, 2025; 393(3):290-300
EDITORIALS（社论）
14
New Perioperative Strategy in Gastric Cancer
胃癌围手术期新策略
K. Shitara
N Engl J Med; July 17, 2025; 393(3):302-303
15
Methotrexate as Initial Therapy for Symptomatic Pulmonary Sarcoidosis?
甲氨蝶呤作为症状性肺结节病的初始治疗？
R.P. Baughman and E.E. Lower
N Engl J Med; July 17, 2025; 393(3):303-305
CORRESPONDENCE（通信）
16
Monoclonal Anti–Platelet Factor 4 Antibodies in Recurrent Pregnancy Loss
单克隆抗血小板因子4抗体在复发性妊娠丢失中的作用
N Engl J Med; July 17, 2025; 393(3):306-309
17
Apixaban for Cancer-Associated Venous Thromboembolism
阿哌沙班治疗癌症相关静脉血栓栓塞
N Engl J Med; July 17, 2025; 393(3):309-312
N Engl J Med[Jour] AND 393[volume] AND 4[issue]
新英格兰医学杂志 393卷4期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
Brain Death in Pregnancy — Abortion, Advance-Directive, or End-of-Life Law?
妊娠期脑死亡——人工流产、预先指示还是临终法律问题？
K. Watson
N Engl J Med; July 24, 2025; 393(4):313-315
2
The Faulty Logic behind the Supreme Court’s Failure to Protect Trans Minors
最高法院未能保护跨性别未成年人的逻辑谬误
S. Skinner-Thompson
N Engl J Med; July 24, 2025; 393(4):316-318
3
The Promise of Real-World Data for Research — What Are We Missing?
现实世界数据研究的前景——我们错过了什么？
A.B. Abbasi , L.H. Curtis , and R.M. Califf
N Engl J Med; July 24, 2025; 393(4):318-321
4
Avocado and Salt
鳄梨和盐
G. Yi
N Engl J Med; July 24, 2025; 393(4):321-323
ORIGINAL ARTICLES(论著)
5
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy
未接受胰岛素治疗的2型糖尿病患者的每周固定剂量艾塞那肽胰岛素
J. Rosenstock and Others
N Engl J Med; July 24, 2025; 393(4):325-335
6
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
德曲妥珠单抗或雷莫芦单抗联合紫杉醇治疗胃癌
K. Shitara and Others
N Engl J Med; July 24, 2025; 393(4):336-348
7
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
塔拉他单抗在小细胞肺癌铂基化疗后的疗效
G. Mountzios and Others
N Engl J Med; July 24, 2025; 393(4):349-361
8
Ivermectin to Control Malaria — A Cluster-Randomized Trial
伊维菌素控制疟疾-一项集群随机试验
C. Chaccour and Others
N Engl J Med; July 24, 2025; 393(4):362-375
REVIEW ARTICLE(综述)
9
Medical Education: Competency-Based Medical Education at the Front Lines of Patient Care
医学教育：位于患者护理第一线的基于能力的医学教育
D. Cooper and E.S. Holmboe
N Engl J Med; July 24, 2025; 393(4):376-388
IMAGES IN CLINICAL MEDICINE(临床医学影像)
10
Löfgren’s Syndrome
洛夫格伦综合征
M. Hassan
N Engl J Med; July 24, 2025; 393(4):389
11
Hydroxychloroquine Retinal Toxicity
羟氯喹视网膜毒性
A. Donnelly and N. Horgan
N Engl J Med; July 24, 2025; 393(4):e4
INTERACTIVE MEDICAL CASE(互动式医疗案例)
12
A Case of Crackles
一例啰音病例
J.I. Hsu and Others
N Engl J Med; July 24, 2025; 393(4):e5
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马赛诸塞州总医院病例记录）
13
Case 21-2025: A 75-Year-Old Man with Cough, Dyspnea, and Hypoxemia
病例21-2025:75岁男性，咳嗽、呼吸困难伴低氧血症
A.M. Anandaiah and Others
N Engl J Med; July 24, 2025; 393(4):390-399
EDITORIALS(社论)
14
Weekly Insulins and Therapeutic Burden in Type 2 Diabetes
每周胰岛素与2型糖尿病的治疗负担
J.R. Ingelfinger and C.J. Rosen
N Engl J Med; July 24, 2025; 393(4):401-402
15
Ivermectin against Malaria — Good News in Bad Times
伊维菌素抗疟疾——艰难时期的好消息
R.W. Steketee
N Engl J Med; July 24, 2025; 393(4):402-404
CLINICAL DECISIONS(临床决策)
16
Statin Therapy for Children
儿童他汀类药物治疗
H.K. Marwah, I.K. Luirink , and M. Mietus-Snyder
N Engl J Med; July 24, 2025; 393(4):405-407
CORRESPONDENCE(通信)
17
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
奥比妥珠单抗治疗活动性狼疮性肾炎的疗效和安全性
N Engl J Med; July 24, 2025; 393(4):408-410
18
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
Lepodisiran -一种靶向脂蛋白(A)的长效干扰性小RNA
N Engl J Med; July 24, 2025; 393(4):411-412
19
BCG Revaccination to Prevent Tuberculosis
卡介苗复种预防结核病
N Engl J Med; July 24, 2025; 393(4):412-413
20
Evolving Epidemiology of Mpox in Africa in 2024
2024年非洲猴痘流行病学演变
N Engl J Med; July 24, 2025; 393(4):414
21
Enteral Nutrition in Hospitalized Adults
住院成人肠内营养
N Engl J Med; July 24, 2025; 393(4):415-416
N Engl J Med[Jour] AND 393[volume] AND 5[issue]
新英格兰医学杂志 393卷5期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
Revised Recommendations for Covid-19 Vaccines — U.S. Vaccination Policy under Threat
Covid-19疫苗修订建议——美国疫苗接种政策受到威胁
J.L. Schwartz
N Engl J Med; July 31, 2025; 393(5):417-419
2
Public Policies, Social Narratives, and Population Health
公共政策、社会叙事与人口健康
A.S. Venkataramani , P.S. Tamber , and A. Iton
N Engl J Med; July 31, 2025; 393(5):419-421
3
Into the Valley of the Sick
进入病痛的之谷
S. Wesloh
N Engl J Med; July 31, 2025; 393(5):421-423
4
Interactive Perspective: Human Papillomavirus and Cancer
互动视角：人类乳头瘤病毒与癌症
J.R. Barzilay and Others
N Engl J Med; July 31, 2025; 393(5):e6
ORIGINAL ARTICLES(论著)
5
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
可测量的残留疾病–指导新诊断的骨髓瘤治疗
A. Perrot and Others
N Engl J Med; July 31, 2025; 393(5):425-437
6
Mitochondrial Donation and Preimplantation Genetic Testing for mtDNA Disease
线粒体捐献和植入前mtDNA疾病基因检测
L.A. Hyslop and Others
N Engl J Med; July 31, 2025; 393(5):438-449
7
A Randomized Trial of Acute Normovolemic Hemodilution in Cardiac Surgery
心脏手术中急性等容血稀释的随机试验
F. Monaco and Others
N Engl J Med; July 31, 2025; 393(5):450-460
8
Brief Report: Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease
简要报告：线粒体捐赠在mtDNA疾病的生殖保健途径
R. McFarland and Others
N Engl J Med; July 31, 2025; 393(5):461-468
9
Brief Report: Resolution of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling
简要报告：通过恢复t细胞受体信号传导来解决鳞状细胞癌
P. Ye and Others
N Engl J Med; July 31, 2025; 393(5):469-478
REVIEW ARTICLE(综述文章)
10
Motor Vehicle Crash Prevention
预防机动车辆碰撞
S.G. Klauer and Z.R. Doerzaph
N Engl J Med; July 31, 2025; 393(5):479-486
IMAGES IN CLINICAL MEDICINE(临床医学影像)
11
Spontaneous Intracranial Hypotension
自发性颅内低血压
S.B. Owais and Y. Kianirad
N Engl J Med; July 31, 2025; 393(5):487
12
Spiderweb-like Vessels in Retinopathy of Prematurity
早产儿视网膜病变中的蜘蛛网状血管
X. Zhao and G. Zhang
N Engl J Med; July 31, 2025; 393(5):e7
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马赛诸塞州总医院病例记录）
13
Case 22-2025: A 19-Year-Old Woman with Seizurelike Activity and Odd Behaviors
案例22-2025：一名19岁女性出现癫痫样活动和怪异行为
J.A. Restrepo and Others
N Engl J Med; July 31, 2025; 393(5):488-496
EDITORIALS(社论)
14
Opening the Door to Tailored Treatment in Newly Diagnosed Multiple Myeloma
开启新诊断多发性骨髓瘤个性化治疗的大门
P.G. Richardson , N.C. Munshi , and D.L. Longo
N Engl J Med; July 31, 2025; 393(5):498-500
15
Reducing the Risks of Mitochondrial Disease in Children
降低儿童线粒体疾病的风险
R. Lovell-Badge
N Engl J Med; July 31, 2025; 393(5):500-503
16
Science behind the Study: Advances in Preventing Transmission of Mitochondrial DNA Diseases
研究背后的科学：预防线粒体DNA疾病传播的进展
J. Steffann
N Engl J Med; July 31, 2025; 393(5):503-507
MEDICINE AND SOCIETY(医学与社会)
17
Reform and Remedy for Imprecision and Inequity — Ending the Race-Based Evaluation of Occupational Pulmonary Impairment
改革与修正——终结基于种族的职业性肺功能障碍评估
R. Khazanchi and Others
N Engl J Med; July 31, 2025; 393(5):508-514
CORRESPONDENCE(通信)
18
Phase 2a Study of Baxdrostat in Primary Aldosteronism
巴司他治疗原发性醛固酮增多症的2a期研究
N Engl J Med; July 31, 2025; 393(5):515-518
19
Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation
脉冲场或低温球囊消融治疗阵发性心房颤动
N Engl J Med; July 31, 2025; 393(5):518-520
N Engl J Med[Jour] AND 393[volume] AND 6[issue]
新英格兰医学杂志 393卷6期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
The Corporatization of U.S. Health Care: A Gilded Age for Patients? The Broken Promises of Profit-Driven Medicine
美国医疗保健公司化：病人的镀金时代？利润驱动的医药破碎的承诺
N. Tomes
N Engl J Med;August 7,2025;393(6):521-524
2
Lead Contamination in Milwaukee Schools — The Latest Episode in an Ongoing Toxic Pandemic
密尔沃基学校的铅污染——正在进行的毒性大流行的最新事件
M.S. Kanarek
N Engl J Med;August 7,2025;393(6):524-526
3
Training Health Communicators — The Need for a New Approach
培训健康传播者——需要一种新的方法
K. Panthagani and Others
N Engl J Med;August 7,2025;393(6):526-529
4
ER and Me
急诊室和我
E. Rourke
N Engl J Med;August 7,2025;393(6):529-531
ORIGINAL ARTICLES(论著)
5
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
芬尼酮联合恩格列净治疗慢性肾病和2型糖尿病
R. Agarwal and Others
N Engl J Med;August 7,2025;393(6):533-543
6
Ciprofloxacin versus Aminoglycoside–Ciprofloxacin for Bubonic Plague
环丙沙星与氨基糖苷-环丙沙星治疗黑死病
R.V. Randremanana and Others
N Engl J Med;August 7,2025;393(6):544-555
7
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Vepdegestrant：一种用于晚期乳腺癌的PROTAC雌激素受体降解剂
M. Campone and Others
N Engl J Med;August 7,2025;393(6):556-568
8
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
一线用药卡米兹斯特兰治疗新发ESR1突变的晚期乳腺癌
F.-C. Bidard and Others
N Engl J Med;August 7,2025;393(6):569-580
REVIEW ARTICLE(综述)
9
Testosterone Treatment in Middle-Aged and Older Men with Hypogonadism
中老年低促性腺激素性腺功能减退症患者的睾酮治疗
S. Bhasin and P.J. Snyder
N Engl J Med;August 7,2025;393(6):581-591
IMAGES IN CLINICAL MEDICINE(临床医学影像)
10
E-Cigarette– or Vaping-Associated Lung Injury
电子烟–或吸电子烟–相关肺损伤
M.Z. Roslly and S.A. Syed Rozhan
N Engl J Med;August 7,2025;393(6):592
11
Crusted Scabies
陈年的疥疮
Y.-J. Sun and H. Gong
N Engl J Med;August 7,2025;393(6):e8
CLINICAL PROBLEM-SOLVING(临床问题解决)
12
Gasping for Strength
喘息求生
D. Zarhin , H. Kolb , and A. Gadoth
N Engl J Med;August 7,2025;393(6):593-599
EDITORIALS(社论)
13
Combination Therapy for Chronic Kidney Disease and Type 2 Diabetes — A Promising Prelude
慢性肾病和2型糖尿病的联合治疗——充满希望的前奏
C. Zoccali and F. Mallamaci
N Engl J Med;August 7,2025;393(6):601-602
14
Chipping Away at an Old Foe
逐步击破旧敌
P. Mead
N Engl J Med;August 7,2025;393(6):603-604
15
Science behind the Study: Degradation of the Estrogen Receptor in Breast Cancer
研究背后的科学：乳腺癌中雌激素受体的降解
D.P. McDonnell
N Engl J Med;August 7,2025;393(6):604-608
MEDICINE AND SOCIETY(医学与社会)
16
Restoring the Infant Mortality Rate as a Measure of Societal Health and Well-Being
恢复将婴儿死亡率作为衡量社会健康和福祉的一项指标
E.A. Harrison , U. Ndulue , and B.O. Ojikutu
N Engl J Med;August 7,2025;393(6):609-614
CORRESPONDENCE(通信)
17
Xenon — Propelling Climbers to the Summits of the World’s Highest Mountains?
氙气—推动登山者登顶世界最高的山脉？
N Engl J Med;August 7,2025;393(6):615-616
18
Daratumumab for High-Risk Smoldering Multiple Myeloma
达雷妥尤单抗用于高危沉默型多发性骨髓瘤
N Engl J Med;August 7,2025;393(6):616-617
19
A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
2型糖尿病患者自动胰岛素输送的随机试验
N Engl J Med;August 7,2025;393(6):617-619
20
Enhanced CAR T-Cell Therapy for Relapsed Lymphoma
增强型CAR T细胞疗法治疗复发性淋巴瘤
N Engl J Med;August 7,2025;393(6):619-620
21
Malaria
疟疾
N Engl J Med;August 7,2025;393(6):620-621
22
Neonatal Fc Receptor — Biology and Therapeutics
新生儿Fc受体——生物学与治疗
N Engl J Med;August 7,2025;393(6):621-623
NEngl J Med[Jour] AND 393[volume] AND 7[issue]
新英格兰医学杂志 393卷7期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
Dismantling Public Health Infrastructure, Endangering American Lives
拆除公共卫生基础设施危及美国人的生命
T.R. Frieden
N Engl J Med;August 14,2025;393(7):625-627
2
Progress Lost — The Unraveling of Medicaid and the Affordable Care Act
停滞不前——医疗补助和《平价医疗法案》的瓦解
J. Oberlander
N Engl J Med;August 14,2025;393(7):628-629
3
The Resurgence of Private Law in American Health Care
美国医疗保健私法的复兴
C. Robertson and W.N. Epstein
N Engl J Med;August 14,2025;393(7):630-631
4
The Serendipitous Dance between Life and Death
生与死之间的偶然之舞
A. Zorigtbaatar
N Engl J Med;August 14,2025;393(7):632-633
ORIGINAL ARTICLES(论著)
5
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Cagrilintide和Semaglutide联合应用于超重或肥胖的成人
W.T. Garvey and Others
N Engl J Med;August 14,2025;393(7):635-647
6
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Cagrilintide–Semaglutide在超重或肥胖和2型糖尿病成人中的应用
M.J. Davies and Others
N Engl J Med;August 14,2025;393(7):648-659
7
A Crossover Trial of Hospital-Wide Lactated Ringer’s Solution versus Normal Saline
医院范围内的乳酸林格氏溶液与生理盐水的交叉试验
L. McIntyre and Others
N Engl J Med;August 14,2025;393(7):660-670
8
Risdiplam in Presymptomatic Spinal Muscular Atrophy
Risdiplam治疗亚临床脊髓性肌萎缩症
R.S. Finkel and Others
N Engl J Med;August 14,2025;393(7):671-682
REVIEW ARTICLE(综述)
9
Metabolic Dysfunction–Associated Steatotic Liver Disease
代谢功能障碍相关脂肪性肝病
G. Targher , L. Valenti , and C.D. Byrne
N Engl J Med;August 14,2025;393(7):683-698
IMAGES IN CLINICAL MEDICINE(临床医学影像)
10
Snowman Sign in Pituitary Macroadenoma
垂体巨腺瘤的雪人征
Y. Zhou and W. Weng
N Engl J Med;August 14,2025;393(7):699
11
Ocular Gnathostomiasis
眼型囊尾蚴病
S. Karkhur and A. Gupta
N Engl J Med;August 14,2025;393(7):e9
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马萨诸塞州总医院病例记录)
12
Case 23-2025: A 28-Year-Old Woman with Respiratory Failure and Abnormal Chest Imaging
病例23-2025：一例28岁女性，呼吸衰竭伴胸部影像异常
W.J. Janssen and Others
N Engl J Med;August 14,2025;393(7):700-710
EDITORIALS(社论)
13
Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care
扩展肥胖和糖尿病的治疗目标工具箱
C.M. Hales
N Engl J Med;August 14,2025;393(7):712-714
14
Science behind the Study: Presymptomatic Treatment of a Genetic Disease with a Small-Molecule Drug
研究背后的科学：小分子药物在遗传性疾病亚临床阶段中的治疗
C.J. Sumner
N Engl J Med;August 14,2025;393(7):714-717
15
Reviewers for the Journal, January–June 2025
本杂志2025年1月至6月的审稿人
E.J. Rubin
N Engl J Med;August 14,2025;393(7):718
CLINICAL DECISIONS(临床决策)
16
Managing Obesity
肥胖治疗
C.P. Kotanidis , A.M. Lincoff , and S.A. Shikora
N Engl J Med;August 14,2025;393(7)::719-721
CORRESPONDENCE(通信)
17
A Naturally Occurring Gain-of-Function Mutation in Factor VIII
因子VIII中自然发生的功能获得突变
N Engl J Med;August 14,2025;393(7):722-724
18
Oral Semaglutide and Cardiovascular Outcomes
口服司美格鲁肽与心血管预后
N Engl J Med;August 14,2025;393(7):724-725
19
Lorundrostat Efficacy and Safety in Uncontrolled Hypertension
Lorundrostat在未控制的高血压中的疗效和安全性
N Engl J Med;August 14,2025;393(7):725-727
20
Cancer of Unknown Primary Site
原发部位不明的癌症
N Engl J Med;August 14,2025;393(7):727-728
N Engl J Med[Jour] AND 393[volume] AND 8[issue]
新英格兰医学杂志 393卷 8期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Preventive Care at the Supreme Court
最高法院谈预防性医疗
N. Bagley
N Engl J Med; Aug 21/28, 2025; 393(8)：729-731
2
Regulating Private Equity in Health Care — The Massachusetts Model
医疗保健领域私募股权的监管——马萨诸塞模式
T.C. Tsai , G.S. Meyer , and D. Blumenthal
N Engl J Med; Aug 21/28, 2025; 393(8)：731-733
3
Reforming the Prescription Drug User Fee Program
改革处方药用户费用计划
T.J. Ziaks and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：734-736
4
The Consultant
顾问视角
T. Adzemovic
N Engl J Med; Aug 21/28, 2025; 393(8)：736-739
ORIGINAL ARTICLES（论著）
5
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
纳武利尤单抗联合化疗新辅助治疗肺癌的总生存期
P.M. Forde and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：741-752
6
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
艾琳扎奈坦特用于乳腺癌内分泌治疗引起的血管舒缩症状
F. Cardoso and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：753-763
7
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
吸入莫格拉斯汀治疗自身免疫性肺泡蛋白沉积症的3期试验
B.C. Trapnell and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：764-773
8
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
西米普利单抗辅助治疗对比安慰剂用于高危皮肤鳞状细胞癌
D. Rischin and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：774-785
REVIEW ARTICLE（综述）
9
Medical Education: Educational Strategies for Clinical Supervision of Artificial Intelligence Use
医学教育：人工智能应用临床监督的教育策略
R.-E.E. Abdulnour , B. Gin , and C.K. Boscardin
N Engl J Med; Aug 21/28, 2025; 393(8)：786-797
IMAGES IN CLINICAL MEDICINE（临床医学影像）
10
Paraganglioma in the Organ of Zuckerkandl
颈动脉体旁器官副神经节瘤
R. Cohen and P. Hammill
N Engl J Med; Aug 21/28, 2025; 393(8)：798
11
Abdominojugular Reflux Test
腹颈静脉回流试验
S. Bent and G. Dhaliwal
N Engl J Med; Aug 21/28, 2025; 393(8)：e10
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
12
Case 24-2025: A 32-Year-Old Woman with Fatigue and Myalgias
2025年第24例病例：一例32岁女性，疲劳伴肌痛
D.G. Kwolek and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：799-807
EDITORIALS（社论）
13
Redefining Lung Cancer Therapy — A Long-Awaited Shift in Strategy
重新定义肺癌治疗——期待已久的策略转变
V. Calvo
N Engl J Med; Aug 21/28, 2025; 393(8)：809-810
14
Menopausal Symptom Management in Breast Cancer Survivors — A Promising New Option
乳腺癌幸存者的更年期症状管理——一种有前景的新选择
A.H. Partridge
N Engl J Med; Aug 21/28, 2025; 393(8)：810-812
15
Science behind the Study: GM-CSF in Autoimmune Pulmonary Alveolar Proteinosis
研究背后的科学：GM-CSF在自身免疫性肺泡蛋白沉积症中的作用
J.F. Seymour
N Engl J Med; Aug 21/28, 2025; 393(8)：812-816
SOUNDING BOARD（讨论专区）
16
The Path Forward for Vaccine Policy in the United States
美国疫苗政策的未来之路
H.Y. Chu and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：817-822
CORRESPONDENCE（读者来信）
17
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy
抗BCMA CAR-T细胞治疗后CAR+ T细胞淋巴瘤的靶向治疗
N Engl J Med; Aug 21/28, 2025; 393(8)：823-825
18
Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
司美格鲁肽治疗代谢相关脂肪性肝炎
N Engl J Med; Aug 21/28, 2025; 393(8)：826-828
19
Omitting Nodal Irradiation after Nodes Clear
淋巴结清除后省略淋巴结放疗
N Engl J Med; Aug 21/28, 2025; 393(8)：828-829
20
AAV Gene Therapy in Severe Hemophilia B
严重血友病B的腺相关病毒（AAV）基因治疗
N Engl J Med; Aug 21/28, 2025; 393(8)：829-830
21
Screening for Prostate Cancer with a Polygenic Risk Score
基于多基因风险评分的前列腺癌筛查
N Engl J Med; Aug 21/28, 2025; 393(8)：831-832
CORRECTION（更正）
22
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
恩扎卢胺改善生化复发前列腺癌的预后
N Engl J Med; Aug 21/28, 2025; 393(8)：832
N Engl J Med[Jour] AND 393[volume] AND 9[issue]
新英格兰医学杂志 393卷 9期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Corporatization of U.S. Health Care: The Corporatization Deal — Health Care, Investors, and the Profit Priority
美国医疗保健的企业化：企业化交易——医疗保健、投资者与利润优先
A. Chandra and M. Shepard
N Engl J Med; Sep 4, 2025; 393(9)：833-835
2
Advancing Physician-Scientist Training in China — Challenges, Gaps, and Future Directions
推进中国医师科学家培养——挑战、差距与未来方向
P. Li and Others
N Engl J Med; Sep 4, 2025; 393(9)：836-838
3
The Rise of Drug Innovation in China — Implications for Patient Access in the United States and Globally
中国药物创新的崛起——对美国及全球患者药物可及性的影响
K.N. Vokinger , G. Li , and O.J. Wouters
N Engl J Med; Sep 4, 2025; 393(9)：839-841
ORIGINAL ARTICLES（论著）
4
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
每月一次的马里德巴特卡弗拉鲁肽治疗肥胖——一项2期试验
A.M. Jastreboff and Others
N Engl J Med; Sep 4, 2025; 393(9)：843-857
5
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
干细胞衍生的完全分化胰岛用于治疗1型糖尿病
T.W. Reichman and Others
N Engl J Med; Sep 4, 2025; 393(9)：858-868
6
One Dose versus Three Doses of Benzathine Penicillin G in Early Syphilis
早期梅毒治疗中苄星青霉素G单次剂量与三次剂量的对比
E.W. Hook III and Others
N Engl J Med; Sep 4, 2025; 393(9)：869-878
7
Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia
单克隆抗体在肝素诱导的血小板减少症发病机制中的作用
J. Treverton and Others
N Engl J Med; Sep 4, 2025; 393(9)：879-886
8
Brief Report: Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression
简短报告：无需免疫抑制的移植同种异体β细胞存活情况
P.-O. Carlsson and Others
N Engl J Med; Sep 4, 2025; 393(9)：887-894
REVIEW ARTICLE（综述）
9
Management of Acute Type B Aortic Dissection
急性B型主动脉夹层的管理
F.F. Mussa and P. Kougias
N Engl J Med; Sep 4, 2025; 393(9)：895-905
VIDEOS IN CLINICAL MEDICINE（临床医学视频）
10
Ultrasound-Guided Paracentesis
超声引导下腹腔穿刺术
A. Kumar and Others
N Engl J Med; Sep 4, 2025; 393(9)：e11
IMAGES IN CLINICAL MEDICINE（临床医学图像）
11
Popeye Sign in Transthyretin Amyloidosis
转甲状腺素蛋白淀粉样变性中的“大力水手”征
S. Kurisu and H. Fujiwara
N Engl J Med; Sep 4, 2025; 393(9)：906
12
Radiation Pneumonitis
放射性肺炎
M. Peters and P. Jeene
N Engl J Med; Sep 4, 2025; 393(9)：e12
13
Hutchinson’s Sign in Subungual Melanoma In Situ
甲下原位黑色素瘤的Hutchinson征
M. Pasch and J. Tutein Nolthenius
N Engl J Med; Sep 4, 2025; 393(9)：e13
CLINICAL PROBLEM-SOLVING（疑难杂症求解探微）
14
A Fruitful Workup
卓有成效的检查过程
N. Jain and Others
N Engl J Med; Sep 4, 2025; 393(9)：907-914
EDITORIALS（社论）
15
A Tale of Two Diseases
两种疾病的故事
M.L. Collazo-Clavell
N Engl J Med; Sep 4, 2025; 393(9)：916-917
16
Science behind the Study: Replacement of Beta Cells for Type 1 Diabetes
研究背后的科学：1型糖尿病的β细胞替代
K.C. Herold and J.S. Pober
N Engl J Med; Sep 4, 2025; 393(9)：917-921
17
Antiquated Tools to Fight an Ancient Foe
用陈旧工具对抗古老敌人
L.A. Barbee and L.H. Bachmann
N Engl J Med; Sep 4, 2025; 393(9)：921-923
CORRESPONDENCE（通信）
18
Fulminant Viral Myocarditis Associated with Thogotovirus
与托高托病毒相关的暴发性病毒性心肌炎
N Engl J Med; Sep 4, 2025; 393(9)：924-926
19
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
奥比西特拉匹在高心血管风险患者中的安全性与有效性
N Engl J Med; Sep 4, 2025; 393(9)：926-928
20
Porcine Xenotransplantation in End-Stage Kidney Disease
终末期肾病中的猪异种移植
N Engl J Med; Sep 4, 2025; 393(9)：929-931
21
Malnutrition in Older Adults
老年人营养不良
N Engl J Med; Sep 4, 2025; 393(9)：931-933
22
Generative AI in Medicine
医学中的生成式人工智能
N Engl J Med; Sep 4, 2025; 393(9)：933-935
N Engl J Med[Jour] AND 393[volume] AND 10[issue]
新英格兰医学杂志 393卷10期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Efforts toward Equity: Caring for Patients with Intellectual or Developmental Disabilities —A Curriculum for Residents
迈向公平的努力：照顾有智力或发育障碍的患者——住院医师培训课程
L. Clarke and Others
N Engl J Med; Sep 11, 2025; 393(10)：937-939
2
Efforts toward Equity: Diaper Need —An Underrecognized Social Driver of Health
迈向公平的努力：尿布需求——一个未被充分认识的社会健康驱动因素
W. Berry , J. Bonville , and S.D. Blatt
N Engl J Med; Sep 11, 2025; 393(10)：939-940
3
Efforts toward Equity: Improving Care Coordination for Indigenous Patients with Cancer
迈向公平的努力：改善对患癌原住民患者的护理协调
A.E. Janitz and Others
N Engl J Med; Sep 11, 2025; 393(10)：940-942
4
Health and Medical Research Funding in a Divided America— How to Increase Support
分裂的美国在卫生与医学研究方面的资金投入——如何增加支持
R.J. Blendon , J.M. Benson , and N.B. Le
N Engl J Med; Sep 11, 2025; 393(10)：942-945
5
The End of Days
末日终结
I.Thomas
N Engl J Med; Sep 11, 2025; 393(10)：945-947
ORIGINAL ARTICLES（论著）
6
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
Aficamten或美托洛尔单药治疗梗阻性肥厚型心肌病
P. Garcia-Pavia and Others
N Engl J Med; Sep 11, 2025; 393(10)：949-960
7
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Mavacamten治疗有症状的非梗阻性肥厚型心肌病
M.Y. Desai and Others
N Engl J Med; Sep 11, 2025; 393(10)：961-972
8
Multidomain Rehabilitation for Older Patients with Myocardial Infarction
针对老年心肌梗死患者的多领域康复治疗
E. Tonet and Others
N Engl J Med; Sep 11, 2025; 393(10)：973-982
9
Marburg Virus Disease in Rwanda, 2024 —Public Health and Clinical Responses
2024年卢旺达的马尔堡病毒病——公共卫生与临床应对措施
S. Nsanzimana and Others
N Engl J Med; Sep 11, 2025; 393(10)：983-993
SPECIAL ARTICLE（专题论著）
10
Medications for Opioid Use Disorder in County Jails —Outcomes after Release
县监狱中阿片类药物使用障碍的治疗药物——释放后的结果
P.D. Friedmann and Others
N Engl J Med; Sep 11, 2025; 393(10)：994-1003
REVIEW ARTICLE（综述）
11
Hypertrophic Cardiomyopathy
肥厚型心肌病
E. Braunwald
N Engl J Med; Sep 11, 2025; 393(10)：1004-1015
IMAGES IN CLINICAL MEDICINE（临床医学影像）
12
Pityriasis Rosea
玫瑰糠疹
E.A. Rallis and C. Verros
N Engl J Med; Sep 11, 2025; 393(10)：1016
13
Acute Epididymo-orchitis in IgA Vasculitis
IgA血管炎伴急性附睾- 睾丸炎
S. Pariha and C. Hanna
N Engl J Med; Sep 11, 2025; 393(10)：e14
14
Ruptured Pulmonary Hydatid Cyst
肺包虫囊肿破裂
Y. Aydin and H. Ogul
N Engl J Med; Sep 11, 2025; 393(10)：e15
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
15
Case 25-2025: A 93-Year-Old Woman with Dyspnea and Fatigue
2025年第25例病例：一例93岁女性，呼吸困难伴疲劳
S.V. Arnold and Others
N Engl J Med; Sep 11, 2025; 393(10)：1017-1024
EDITORIAL（社论）
16
Expanding the Role of Myosin Inhibition in Hypertrophic Cardiomyopathy — A Tale of Two Conditions
扩大肌球蛋白抑制在肥厚型心肌病中的作用——两种疾病的故事
A.V. Ambardekar
N Engl J Med; Sep 11, 2025; 393(10)：1026-1028
MEDICINE AND SOCIETY（医学与社会）
17
The Race-Correction Debates —Progress, Tensions, and Future Directions
种族校正争议——进展、紧张局势和未来方向
D.A. Vyas , L.G. Eisenstein , and D.S. Jones
N Engl J Med; Sep 11, 2025; 393(10)：1029-1036
CORRESPONDENCE（读者来信）
18
Long-Term Outcomes of the DanGer Shock Trial
DanGer休克试验的长期结果
N Engl J Med; Sep 11, 2025; 393(10)：1037-1038
19
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
Efruxifermin治疗MASH所致的代偿性肝硬化
N Engl J Med; Sep 11, 2025; 393(10)：1038-1039
20
Once-Weekly Mazdutide in Obesity or Overweight
每周一次Mazdutide治疗肥胖或超重
N Engl J Med; Sep 11, 2025; 393(10)：1040
N Engl J Med[Jour] AND 393[volume] AND 11[issue]
新英格兰医学杂志 393卷11期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Reducing Tobacco Use Worldwide: Integrating Pharmacotherapy into Tobacco Control in Low- and Middle-Income Countries — A Critical Need
全球范围内减少烟草使用：将药物治疗纳入中低收入国家烟草控制——一项迫切需求
N.A. Rigotti , N. Walker , and A.S. Amer Nordin
N Engl J Med; Sep 18, 2025; 393(11)：1041-1044
2
Protecting Medicaid Enrollees with Chronic Conditions amid Work Requirements
在工作要求下保护患有慢性病的医疗补助计划（Medicaid）参保人
J.Z. Ayanian
N Engl J Med; Sep 18, 2025; 393(11)：1044-1046
3
Ultraprocessed Food on an Ultrafast Track
超加工食品驶入超速发展轨道
D.S. Ludwig
N Engl J Med; Sep 18, 2025; 393(11)：1046-1049
4
The Consequences of Silencing the “Voice of CDC”
“美国疾控中心之声”被消音的后果
S.A. Rasmussen and Others
N Engl J Med; Sep 18, 2025; 393(11)：e16
5
Medicaid on the Chopping Block
医疗补助计划（Medicaid）面临削减
E. Park
N Engl J Med; Sep 18, 2025; 393(11)：e17
ORIGINAL ARTICLES（论著）
6
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
低剂量阿司匹林用于PI3K突变的局限性结直肠癌
A. Martling and Others
N Engl J Med; Sep 18, 2025; 393(11)：1051-1064
7
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Orforglipron（一种口服小分子GLP-1受体激动剂）用于早期2型糖尿病
J. Rosenstock and Others
N Engl J Med; Sep 18, 2025; 393(11)：1065-1076
8
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
口服司美格鲁肽25 mg用于超重或肥胖成人
S. Wharton and Others
N Engl J Med; Sep 18, 2025; 393(11)：1077-1087
9
Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation
比例辅助通气以缩短机械通气时间
K.J. Bosma and Others
N Engl J Med; Sep 18, 2025; 393(11)：1088-1103
REVIEW ARTICLE（综述）
10
Tumor Lysis Syndrome
肿瘤溶解综合征
R.G. Bociek and M. Lunning
N Engl J Med; Sep 18, 2025; 393(11)：1104-1116
IMAGES IN CLINICAL MEDICINE（临床医学影像）
11
Subcutaneous Panniculitis-like T-Cell Lymphoma
皮下脂膜炎样T细胞淋巴瘤
S. Okada and M. Nishikubo
N Engl J Med; Sep 18, 2025; 393(11)：1117
12
Primary Varicella Infection
原发性水痘感染
O. van Not and D. Rauwerdink
N Engl J Med; Sep 18, 2025; 393(11)：e18
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
13
Case 26-2025: An 11-Year-Old Girl with Chest Pain and Bone and Liver Lesions
2025年第26例病例：一例11岁女孩，胸痛伴骨和肝脏病变
L.P. Carter and Others
N Engl J Med; Sep 18, 2025; 393(11)：1118-1127
EDITORIALS（社论）
14
Reducing Tobacco Use Worldwide — A New Perspective Series
全球减少烟草使用——新观点系列
N.A. Rigotti and Others
N Engl J Med; Sep 18, 2025; 393(11)：1129-1130
15
An Aspirin a Day for Improved Colorectal Cancer Outcomes
每日一片阿司匹林以改善结直肠癌预后
R.M. Goldberg and J.A. Meyerhardt
N Engl J Med; Sep 18, 2025; 393(11)：1131-1132
16
Mimicking Complex Receptor Actions with Small(ish) Molecules
用小（型）分子模拟复杂受体作用
D.B. Lowe
N Engl J Med; Sep 18, 2025; 393(11)：1133-1134
CORRESPONDENCE（通信）
17
Introduction of Mpox Virus Clade Ib into the Republic of the Congo
猴痘病毒Ib分支传入刚果共和国
N Engl J Med; Sep 18, 2025; 393(11)：1135-1137
18
Perioperative Pembrolizumab in Head and Neck Cancer
围手术期帕博利珠单抗用于头颈癌
N Engl J Med; Sep 18, 2025; 393(11)：1138-1139
19
Ondansetron after ED Visits in Children with Gastroenteritis
儿童胃肠炎急诊就诊后使用昂丹司琼
N Engl J Med; Sep 18, 2025; 393(11)：1139-1141
20
Navigating the Discontinuity Crisis in Medical Education
应对医学教育中的断层危机
N Engl J Med; Sep 18, 2025; 393(11)：1141-1143
21
Fetal Hereditary Thrombotic Thrombocytopenic Purpura
胎儿遗传性血栓性血小板减少性紫癜
N Engl J Med; Sep 18, 2025; 393(11)：1143-1144
N Engl J Med[Jour] AND 393[volume] AND 12[issue]
新英格兰医学杂志 393卷12期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Structural and Scientific Racism, Science, and Health — Evidence versus Ideology
结构性与科学层面的种族主义、科学与健康——证据与意识形态之争
N. Krieger and M.T. Bassett
N Engl J Med; Sep 25, 2025; 393(12)：1145-1148
2
From Health to Wealth — Reframing Global Aid through the Gates Foundation’s Final Chapter
从健康到财富——通过盖茨基金会的终章重新构建全球援助框架
S. Phillips
N Engl J Med; Sep 25, 2025; 393(12)：1148-1151
3
Dr. Kolhouse and the Cowboy
科尔豪斯博士与牛仔
M. Earnest
N Engl J Med; Sep 25, 2025; 393(12)：1151-1153
ORIGINAL ARTICLES（论著）
4
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction
地高辛用于射血分数降低的心力衰竭患者
U. Bavendiek and Others
N Engl J Med; Sep 25, 2025; 393(12)：1155-1165
5
Apixaban for Extended Treatment of Provoked Venous Thromboembolism
阿哌沙班用于诱因性静脉血栓栓塞症的延长治疗
G. Piazza and Others
N Engl J Med; Sep 25, 2025; 393(12)：1166-1176
6
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
基于可测量残留病灶指导的慢性淋巴细胞白血病治疗
T. Munir and Others
N Engl J Med; Sep 25, 2025; 393(12)：1177-1190
7
Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke
卒中静脉溶栓后早期输注替罗非班
C. Tao and Others
N Engl J Med; Sep 25, 2025; 393(12)：1191-1201
REVIEW ARTICLE（综述）
8
Medical Education: Advancing Diagnostic Excellence through Medical Education in Diagnostic Equity
医学教育：通过诊断公平性医学教育推进诊断卓越
D.M. Connor , M.L. Lypson , and C.M. Gonzalez
N Engl J Med; Sep 25, 2025; 393(12)：1202-1214
IMAGES IN CLINICAL MEDICINE（临床医学影像）
9
Systemic Mastocytosis
系统性肥大细胞增多症
L. Neves da Silva and A.M. Monteiro
N Engl J Med; Sep 25, 2025; 393(12)：1215
10
Doxycycline-Induced Phototoxicity
多西环素诱导的光毒性反应
G. Boyd and C. Cheng
N Engl J Med; Sep 25, 2025; 393(12)：e19
INTERACTIVE MEDICAL CASE（互动式医学病例）
11
A Fizzy Fix
气泡疗法
M.A. Crane and Others
N Engl J Med; Sep 25, 2025; 393(12)：e20
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
12
Case 27-2025: A 53-Year-Old Man with Embolic Stroke and Left Ventricular Apical Aneurysm
2025年第27例病例：一例53岁男性，患有栓塞性卒中及左心室心尖部动脉瘤
G.C. Stewart and Others
N Engl J Med; Sep 25, 2025; 393(12)：1216-1225
EDITORIALS（社论）
13
Digitoxin — A Reminder for Digoxin
地高辛——对洋地黄的提醒
M.A. Pfeffer
N Engl J Med; Sep 25, 2025; 393(12)：1227-1228
14
Art within Evidence — Balancing Anticoagulant Duration in VTE Care
证据中的艺术——平衡静脉血栓栓塞症护理中的抗凝时长
N.A. Zakai
N Engl J Med; Sep 25, 2025; 393(12)：1229-1230
CLINICAL IMPLICATIONS OF BASIC RESEARCH（基础研究的临床意义）
15
Transformative Research in Cystic Fibrosis
囊性纤维化的变革性研究
E.J. Sorscher
N Engl J Med; Sep 25, 2025; 393(12)：1231-1234
16
Surprisingly Complex Assemblies from Low-Complexity Domains
来自低复杂度结构域的惊人复杂组装
T. Mittag
N Engl J Med; Sep 25, 2025; 393(12)：1235-1238
CORRESPONDENCE（通信）
17
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis
CD19嵌合抗原受体T细胞疗法治疗多重耐药性溃疡性结肠炎
N Engl J Med; Sep 25, 2025; 393(12)：1239-1241
18
Nonoperative Management of Mismatch Repair–Deficient Tumors
错配修复缺陷肿瘤的非手术治疗
N Engl J Med; Sep 25, 2025; 393(12)：1241-1243
19
Cerebral Embolic Protection during TAVI
经导管主动脉瓣置换术中的脑栓塞保护
N Engl J Med; Sep 25, 2025; 393(12)：1243-1245
20
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates
心血管危险因素对终生估计的全球影响
N Engl J Med; Sep 25, 2025; 393(12)：1245-1248
N Engl J Med[Jour] AND 393[volume] AND 13[issue]
新英格兰医学杂志 393卷13期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Corporatization of U.S. Health Care: Insight into Corporate Governance — What Motivates Hospitals and Delivery Systems
美国医疗保健的企业化：企业治理洞察——医院和医疗交付系统的动机何在
S. Lipstein
N Engl J Med; Oct 2, 2025; 393(13)：1249-1251
2
The Risks of Pharmaceutical Tariffs for Generic Drug Availability
药品关税对仿制药供应的风险
T.J. Hwang , Q.-D. Trinh , and K.N. Vokinger
N Engl J Med; Oct 2, 2025; 393(13)：1252-1253
3
Goals for Opioid Use Disorder Medications — Protection, Remission, and Recovery
阿片类药物使用障碍治疗药物的目标——保护、缓解和康复
A.T. McLellan and N.D. Volkow
N Engl J Med; Oct 2, 2025; 393(13)：1253-1255
ORIGINAL ARTICLES（论著）
4
Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis
伴有胃肠炎的严重急性营养不良的静脉补液治疗
K. Maitland and Others
N Engl J Med; Oct 2, 2025; 393(13)：1257-1268
5
Medical Imaging and Pediatric and Adolescent Hematologic Cancer Risk
医学影像与儿童和青少年血液系统癌症风险
R. Smith-Bindman and Others
N Engl J Med; Oct 2, 2025; 393(13)：1269-1278
6
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
使用针对APOC3的奥列扎森治疗中度高甘油三酯血症
B.A. Bergmark and Others
N Engl J Med; Oct 2, 2025; 393(13)：1279-1291
7
Clesrovimab for Prevention of RSV Disease in Healthy Infants
克莱斯罗维玛布预防健康婴儿呼吸道合胞病毒疾病
H.J. Zar and Others
N Engl J Med; Oct 2, 2025; 393(13)：1292-1303
8
Home-Based Care for Hypertension in Rural South Africa
南非农村地区高血压的家庭护理
M.J. Siedner and Others
N Engl J Med; Oct 2, 2025; 393(13)：1304-1314
REVIEW ARTICLE（综述）
9
Monoclonal Gammopathy of Undetermined Significance
意义未定的单克隆丙种球蛋白病
S.V. Rajkumar and S. Kumar
N Engl J Med; Oct 2, 2025; 393(13)：1315-1326
IMAGES IN CLINICAL MEDICINE（临床医学图像）
10
Uremic Frost
尿毒症霜
M.A. Wani and Z.H. Shah
N Engl J Med; Oct 2, 2025; 393(13)：1327
11
Herpes Simplex Virus Esophagitis
单纯疱疹病毒食管炎
A.Agarwal and A. Agarwal
N Engl J Med; Oct 2, 2025; 393(13)：e21
CLINICAL PROBLEM-SOLVING（疑难杂症破解之道）
12
A Shifting Frame
视角转换
A.Terrett and Others
N Engl J Med; Oct 2, 2025; 393(13)：1328-1334
EDITORIALS（社论）
13
Data versus Dogma — Safety of Intravenous Rehydration in Severely Malnourished Children
数据与教条之争——严重营养不良儿童静脉补液的安全性
M.J. Peters
N Engl J Med; Oct 2, 2025; 393(13)：1336-1337
14
Studying Cancer Risks Associated with Diagnostic Procedures — Interpret Wisely
研究诊断程序相关的癌症风险——明智解读
L.M. Morton
N Engl J Med; Oct 2, 2025; 393(13)：1337-1339
CLINICAL DECISIONS（临床决策）
15
Allergy or Assumption of Allergy — When to Test for a Penicillin Allergy
过敏还是假定的过敏——何时进行青霉素过敏测试
H. Marwah , A. Ramsey , and E.M. Macy
N Engl J Med; Oct 2, 2025; 393(13)：1340-1342
CORRESPONDENCE（读者来信）
16
Clesrovimab in Infants and Children at Increased Risk for Severe RSV Disease
克莱斯罗维玛布用于有严重呼吸道合胞病毒疾病高风险的婴儿和儿童
N Engl J Med; Oct 2, 2025; 393(13)：1343-1345
17
Nerandomilast in Patients with Pulmonary Fibrosis
奈拉度米拉司特用于肺纤维化患者
N Engl J Med; Oct 2, 2025; 393(13)：1346-1347
18
Trastuzumab Deruxtecan in Gastric Cancer
德曲妥珠单抗用于胃癌
N Engl J Med; Oct 2, 2025; 393(13)：1347-1348
19
Tarlatamab in Small-Cell Lung Cancer
塔拉他玛布用于小细胞肺癌
N Engl J Med; Oct 2, 2025; 393(13)：1348-1349
20
Cyclophosphamide and Cyclosporin for GVHD Prevention
环磷酰胺和环孢素预防移植物抗宿主病
N Engl J Med; Oct 2, 2025; 393(13)：1349-1351
N Engl J Med[Jour] AND 393[volume] AND 14[issue]
新英格兰医学杂志 393卷14期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Occupational Health and Safety on the Chopping Block — What’s at Stake?
职业健康与安全岌岌可危——有何利害关系？
A.T. Gabrielson and C. Corwin
N Engl J Med; Oct 9, 2025; 393(14)：1353-1355
2
Emergency Medicaid at Risk — Preserving State Authority and Access to Care
紧急医疗补助岌岌可危——维护州政府权限与医疗保障可及性
J.A. Budhu and Others
N Engl J Med; Oct 9, 2025; 393(14)：1356-1358
3
Pharmaceutical Wholesalers — Under-the-Radar Middlemen?
药品批发商——鲜为人知的中间商？
H. Rooke-Ley and R.E. Sachs
N Engl J Med; Oct 9, 2025; 393(14)：1358-1360
4
“You Still Going to Be Doing This?”
“你还会坚持下去吗？”
E.J. Shapiro
N Engl J Med; Oct 9, 2025; 393(14)：1360-1361
ORIGINAL ARTICLES（论著）
5
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension
巴克斯德罗沙特（Baxdrostat）治疗未控制及难治性高血压的疗效与安全性
J.M. Flack and Others
N Engl J Med; Oct 9, 2025; 393(14)：1363-1374
6
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy
针对伴有多发性神经病的遗传性转甲状腺素蛋白淀粉样变性病的Nexiguran Ziclumeran基因编辑疗法
J.D. Gillmore and Others
N Engl J Med; Oct 9, 2025; 393(14)：1375-1386
7
Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases
靶向室内喷洒预防埃及伊蚊传播疾病的随机试验
N.E. Dean and Others
N Engl J Med; Oct 9, 2025; 393(14)：1387-1398
8
Permethrin-Treated Baby Wraps for the Prevention of Malaria
使用氯菊酯处理过的婴儿包裹物预防疟疾
R.M. Boyce and Others
N Engl J Med; Oct 9, 2025; 393(14)：1399-1408
REVIEW ARTICLE（综述）
9
Idiopathic Intracranial Hypertension
特发性颅内压增高
J.C. Horton
N Engl J Med; Oct 9, 2025; 393(14)：1409-1419
IMAGES IN CLINICAL MEDICINE（临床医学影像）
10
Butterfly Vertebra
蝴蝶椎
S. Ding and X. Pan
N Engl J Med; Oct 9, 2025; 393(14)：1420
11
Oral Verruciform Xanthomas
口腔疣状黄瘤
G. Anaya-Saavedra and M. Vázquez-Garduño
N Engl J Med; Oct 9, 2025; 393(14)：e22
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
12
Case 28-2025: A 36-Year-Old Man with Abdominal Pain, Fever, and Hypoxemia
2025年第28例病例：一例36岁男性，出现腹痛、发热伴低氧血症
G. Dhaliwal and Others
N Engl J Med; Oct 9, 2025; 393(14)：1421-1434
EDITORIAL（社论）
13
Aldosterone Synthase Inhibition for Hypertension
醛固酮合成酶抑制剂治疗高血压
T.J. Guzik and M. Tomaszewski
N Engl J Med; Oct 9, 2025; 393(14)：1436-1439
CORRESPONDENCE（读者来信）
14
Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel — Update
Exagamglogene Autotemcel中CRISPR-Cas9编码的特异性——更新
N Engl J Med; Oct 9, 2025; 393(14)：1440-1442
15
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes
每周固定剂量艾氟司他（Efsitora）胰岛素治疗2型糖尿病
N Engl J Med; Oct 9, 2025; 393(14)：1442-1444
16
Diphtheria Outbreak among Migrants in Europe
欧洲移民群体中的白喉疫情
N Engl J Med; Oct 9, 2025; 393(14)：1444-1445
17
Clearance of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling
通过恢复T细胞受体信号传导清除鳞状细胞癌
N Engl J Med; Oct 9, 2025; 393(14)：1446-1447
18
Case 17-2025: A Man with Respiratory Failure and Shock after Kidney Transplantation
2025年第17例病例：一例肾移植后出现呼吸衰竭和休克的患者
N Engl J Med; Oct 9, 2025; 393(14)：1447-1448
N Engl J Med[Jour] AND 393[volume] AND 15[issue]
新英格兰医学杂志 393卷15期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
Reducing Tobacco Use Worldwide: The Contribution of Digital Treatment to Efforts to Reduce Global Tobacco Use
减少全球烟草使用:数字治疗对减少全球烟草使用的贡献
F. Naughton and A. Nadkarni
N Engl J Med; October16, 2025; 393(15):1449-1452
2
Advancing Surveillance of Health Care–Associated Infections — Targeting Hospital-Onset Sepsis
推进卫生保健相关感染的监测-针对医院发生的败血症
F. Manzoor , C. Rhee , and M. Klompas
N Engl J Med; October16, 2025; 393(15):1452-1454
3
The AI Frontier in Humanitarian Aid — Embracing Possibilities and Addressing Risks
人工智能在人道主义援助中的前沿——拥抱可能性与应对风险
M. Barry , J. Hansen , and G.L. Darmstadt
N Engl J Med; October16, 2025; 393(15):1454-1457
4
Proliferation of Prior Authorization in Traditional Medicare — None the WISeR?
传统医疗中预先授权的扩散——更明智了吗？
M. Liu , K.T. Kadakia , and R.K. Wadhera
N Engl J Med; October16, 2025; 393(15):1457-1459
5
On Bearing Witness
关于见证
S. Attar
N Engl J Med; October16, 2025; 393(15):1459-1461
6
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Alive and Kicking — NOS Episode 3.1
未作特别说明（NOS）——第三季：初级医疗的永恒危机：愈演愈烈 ——NOS第3季第1集
N Engl J Med; October16, 2025; 393(15):e24
ORIGINAL ARTICLES(论著)
7
Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer
宫颈癌中仅行前哨淋巴结活检或联合淋巴结清扫术
H. Tu and Others
N Engl J Med; October16, 2025; 393(15):1463-1474
8
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
Telitacicept治疗系统性红斑狼疮的3期临床试验
R.F. van Vollenhoven and Others
N Engl J Med; October16, 2025; 393(15):1475-1485
9
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency
基因治疗腺苷脱氨酶缺乏症的长期安全性和有效性
C. Booth and Others
N Engl J Med; October16, 2025; 393(15):1486-1497
10
Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality
马里婴儿大量使用阿奇霉素以降低死亡率
F.C. Haidara and Others
N Engl J Med; October16, 2025; 393(15):1498-1508
CLINICAL PRACTICE(临床实践)
11
Hair Loss in Women
女性脱发
E.A. Olsen
N Engl J Med; October16, 2025; 393(15):1509-1520
IMAGES IN CLINICAL MEDICINE(临床医学影像)
12
Pneumococcal Sepsis in a Patient with Asplenia and Hypogammaglobulinemia
脾缺失合并低丙种球蛋白血症患者发生肺炎球菌性败血症
S.J. Starke and I. Miller
N Engl J Med; October16, 2025; 393(15):1521
13
Stercoral Colitis
粪石性结肠炎
A. Bajer and E. Levine
N Engl J Med; October16, 2025; 393(15): e23
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马萨诸塞州总医院的病例记录)
14
Case 29-2025: A 43-Year-Old Woman with Depression, Suicidal Ideation, and Fever
病例29-2025：一例43岁女性，抑郁、自杀倾向伴发热
M.S. Abers and Others
N Engl J Med; October16, 2025; 393(15):1522-1531
EDITORIALS(社论)
15
Risk and Benefit
风险与收益
E.J. Rubin
N Engl J Med; October16, 2025; 393(15):1533-1534
16
Sentinel Lymphadenectomy for Early-Stage Cervical Cancer — the New Standard?
早期宫颈癌的前哨淋巴结切除术——新标准？
K. Bixel
N Engl J Med; October16, 2025; 393(15):1534-1536
MEDICINE AND SOCIETY(医学与社会)
17
The Primary Care Puzzle: Is a Long-Simmering Crisis Boiling Over? U.S. Primary Care Today
初级医疗之谜：长期酝酿的危机正在爆发？美国初级医疗现状
L. Rosenbaum
N Engl J Med; October16, 2025; 393(15):1537-1541
CORRESPONDENCE(通信)
18
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
体内CD19 CAR T细胞疗法治疗难治性系统性红斑狼疮
N Engl J Med; October16, 2025; 393(15):1542-1544
19
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
顽固性自身免疫性疾病患者的BCMA T细胞接合疗法
N Engl J Med; October16, 2025; 393(15):1544-1547
20
Competency-Based Medical Education at the Front Lines of Patient Care
以能力为本的一线患者护理医学教育
N Engl J Med; October16, 2025; 393(15):1548-1550
21
More about the Phase 2a Study of Baxdrostat in Primary Aldosteronism
更多关于巴司他治疗原发性醛固酮增多症的2a期研究
N Engl J Med; October16, 2025; 393(15):1550-1552
N Engl J Med[Jour] AND 393[volume] AND 16[issue]
新英格兰医学杂志 393卷16期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Involving Palliative Care to Improve Outcomes in Sickle Cell Disease
纳入姑息治疗以改善镰状细胞病预后
E. Nwogu-Onyemkpa and Others
N Engl J Med; Oct 23, 2025; 393(16)：1553-1556
2
Thirty Years of Hydroxyurea for Sickle Cell Anemia — Scientific Progress, Global Health Gaps
羟基脲治疗镰状细胞贫血三十年——科学进展与全球健康差距
E. Costa and Others
N Engl J Med; Oct 23, 2025; 393(16)：1556-1559
3
Fetal Personhood and Reproductive Criminalization — Implications for Patients, Clinicians, and Public Health
胎儿人格与生殖犯罪化——对患者、临床医生和公共卫生的影响
T. Riley and A. Hassan
N Engl J Med; Oct 23, 2025; 393(16)：1559-1561
4
Living in the Present Tense
活在当下
J.A. Feinstein
N Engl J Med; Oct 23, 2025; 393(16)：1561-1563
5
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Can AI Solve Primary Care? — NOS Episode 3.2
未作他类说明——第三季：初级保健的永恒危机：人工智能能否解决初级保健问题？——未作他类说明第3.2集
N Engl J Med; Oct 23, 2025; 393(16)：e25
ORIGINAL ARTICLES（论著）
6
Hypertonic Saline or Carbocisteine in Bronchiectasis
高渗盐水或羧甲司坦治疗支气管扩张症
J.M. Bradley and Others
N Engl J Med; Oct 23, 2025; 393(16)：1565-1577
7
Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation
接受口服抗凝治疗的慢性冠状动脉综合征患者使用阿司匹林的情况
G. Lemesle and Others
N Engl J Med; Oct 23, 2025; 393(16)：1578-1588
8
Common Diseases in Clinical Cohorts — Not Always What They Seem
临床队列中的常见疾病——并不总是如表面所见
F. Rahimov and Others
N Engl J Med; Oct 23, 2025; 393(16)：1589-1598
9
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis
诊断后第一年内使用索塔生塞普（Sotatercept）治疗肺动脉高压
V.V. McLaughlin and Others
N Engl J Med; Oct 23, 2025; 393(16)：1599-1611
10
Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans
2024-2025年新冠疫苗与美国退伍军人新冠结局的关联
M. Cai , Y. Xie , and Z. Al-Aly
N Engl J Med; Oct 23, 2025; 393(16)：1612-1623
REVIEW ARTICLE（综述）
11
Medical Education: Educational Strategies to Prepare Trainees for Clinical Uncertainty
医学教育：为受训者应对临床不确定性做准备的教育策略
J.S. Ilgen and G. Dhaliwal
N Engl J Med; Oct 23, 2025; 393(16)：1624-1632
IMAGES IN CLINICAL MEDICINE（临床医学影像）
12
Human East African Trypanosomiasis
人类东非锥虫病
L. Veletzky and S. Winkler
N Engl J Med; Oct 23, 2025; 393(16)：1633
13
Thoracic Ectopia Cordis
胸部心脏异位
Z. Duric and H. Gasparovic
N Engl J Med; Oct 23, 2025; 393(16)：e26
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
14
Case 30-2025: An 82-Year-Old Woman with Abdominal Distention, Edema, and Pleural Effusion
2025年30号病例：一名82岁女性，出现腹部膨隆、水肿和胸腔积液
Z. Kanjee and Others
N Engl J Med; Oct 23, 2025; 393(16)：1634-1644
EDITORIALS（社论）
15
Time to Reconsider Mucoactive Agents for Airway Clearance
是时候重新考虑用于气道廓清的黏液活性药物了
J. Hansen-Flaschen and G. Tino
N Engl J Med; Oct 23, 2025; 393(16)：1646-1647
16
A Rare-in-Common Paradigm for Precision Genomic Medicine
精准基因组医学中的“罕见共性”范式
P.N. Robinson
N Engl J Med; Oct 23, 2025; 393(16)：1648-1649
CORRESPONDENCE（读者来信）
17
Resurgence of Zoonotic Highly Pathogenic Avian Influenza A(H5N1) Virus in Cambodia
柬埔寨人畜共患高致病性禽流感A(H5N1)病毒卷土重来
N Engl J Med; Oct 23, 2025; 393(16)：1650-1652
18
Perioperative Durvalumab in Gastric Cancer
胃癌围手术期使用度伐利尤单抗
N Engl J Med; Oct 23, 2025; 393(16)：1652-1654
19
Tirzepatide vs. Semaglutide for Obesity Treatment
替西帕肽与司美格鲁肽治疗肥胖症的对比
N Engl J Med; Oct 23, 2025; 393(16)：1654-1656
临床结果临床2期
2025-10-22
篇一：GLP-1 类药物总览：从已上市经典到临床新锐
从“减肥神药”到“心肾获益”，GLP-1的故事远未结束。 为什么没结束？ 当然是因为最近还有身边人问我GLP-1类药物怎么选？该不该打？（是因为种类太多，挑花眼了么。听医生的建议不好么？）索性准备开一个合集，盘一盘GLP类的肥胖/糖尿病的药物情况。
本系列聚焦“代谢四小龙靶点”：GLP-1、GIP、GCG、Amylin，争取一个系列帮你看清以及对目前代谢领域的明星靶点进行拆解。今天不细讲生物机制靶点通路，先给你们一套三维观察框架，帮助大家快速定位目前（肥胖/2 型糖尿病）相关药物的位置与证据成熟度。后续，应该会针对每一个靶点写一篇专稿，包括但不限于靶点机制，药物研发（背后小故事？），管线情况等。原谅我想到什么就写什么，GLP这个药的研发确实是非常有趣的。老规矩，每一篇最后会有关于该靶点的 全球管线表 梳理，敬请期待，记得点关注嗷~。（本篇预计阅读时间：5 分钟，含 2 张核心管线表）一、为什么从 GLP-1 开场？
在“代谢轴”上，GLP-1 的临床证据最为扎实：体重下降与 HbA1c 双终点表现突出，且在心肾结局、肝脂等外延终点上不断积累长期数据。现实世界中，周制剂 + 口服制剂的组合也让更多人群可及。以此为“地基”，再看 GIP/GCG/Amylin 的叠加与互补，就更容易把握当下研发与临床应用的走向。（Tips：截至 2025-10-22，司美格鲁肽家族的肥胖适应症与替尔泊肽在中国的注册进展，已让“单受体/双受体”的临床应用图景更清晰；同时，国内外多项“口服小分子 GLP-1”与“多受体激动剂”的关键试验仍在推进。）二、用“三维观察框架”看管线
维度 1｜受体维度：单受体（GLP-1 / Amylin）→ 双受体（GLP-1/GIP、GLP-1/GCG）→ 三重（GLP-1/GIP/GCG）。
维度 2｜给药维度：肽类周制剂 → 更长效（半月/月） → 口服肽 / 口服小分子 GLP-1。
维度 3｜证据维度：II 期剂量探索 → III 期确证/注册 → 结局性终点（CV、肾、NASH、OSA 等）。
把任一项目放进这三维，就能迅速判断其相对梯队、差异化路径以及下一关键读数应是什么（例如：是否走向 CV/肾结局、是否需要与同类头对头、是否补齐起始与滴定的耐受资料）。三、已上市概况
司美格鲁肽家族（Ozempic/Rybelsus/Wegovy）：单受体“标准样本”，周制剂 + 口服并存；肥胖长期管理适应症的全球化铺开，为“减重 + 代谢综合获益”提供了现实参照。
替尔泊肽（GLP-1/GIP）：作为双受体代表，在减重与控糖上显示出“强度 + 便利”的优势；中国已完成核心注册节点的获批与拓展。
经典 GLP-1RA 仍在使用：利拉鲁肽、度拉糖肽、艾塞那肽等在不同人群/场景中保有角色（如日常依从、装置熟悉度、费用与可及性等）。
本土里程碑：GLP-1/GCG 双受体在中国完成体重管理适应症的首批；随后 T2D 控糖适应症也陆续落地，提示“能量消耗 + 食欲抑制”的组合正进入临床实践。
小提醒：上市格局读法依然适用于“三维观察框架”。例如：某单受体项目已在“给药维”实现口服化，或某双受体项目在“证据维”进入结局性试验，其定位就会随之上移。
目前诺和诺德与礼来的双寡头格局短期内难以撼动，其产品在疗效和市场准入上拥有先发优势。药物的应用已从2型糖尿病扩展至肥胖、心血管疾病、慢性肾病甚至神经退行性疾病等多个领域，四、临床新锐与今年三件值得跟踪的事
三重受体的边界：以 retatrutide 为代表的三重激动剂已进入多项 III 期；关注的是极限体重下降与长期安全窗口能否被稳健证实。
口服小分子 GLP-1 的落地：多项 III 期结果显示口服方案能达到主要终点，下一步需要观察长期依从、不良反应管理与真实世界持续性。
协同与联用：如 GLP-1 + Amylin 复方在 68 周随访中呈现稳健减重信号；接下来要看在合并症人群（T2D、OSA、NASH 等）的场景化优势是否成立，以及与同类项目的头对头能否提供清晰分层。
中国在研（非全部）：本土企业在“口服小分子 GLP-1”与“GLP-1/GIP 双受体（含 III 期）”“三重激动剂”等方向持续推进，部分项目已披露与国际同类接近的体重下降幅度；也有周制剂 GLP-1 在国内 III 期取得与国际标杆相近的体重下降信号。上述动向总体印证了“多受体 + 口服化”的加速。五、风险与临床实践要点
早期耐受：恶心、呕吐、腹泻等较常见；起始与滴定策略直接影响持续治疗与依从性。
长期窗口：胆道/胰腺信号、心率变化、体成分（肌量）与停药后体重回弹，需中长期随访与真实世界证据支持。
证据等级：优先关注同类头对头试验、结局性终点、经同行评议的长期数据；对仅有早期信号的“多受体组合”保持审慎。六、今天先把“轴”立住
从现有证据与研发方向看，代谢领域（肥胖/糖尿病）的药物开发，确实主要围绕 GLP-1、GIP、GCG、Amylin 这一条“轴”展开：
GLP-1：打基础（控糖、体重、心肾外延）；
GIP：在组合时常见强化作用（特别是与 GLP-1 联用）；
GCG：通过能量消耗与肝代谢通路补齐“体重上限”的短板；
Amylin：在饱腹/胃排空与长期体重管理情境中提供支撑。
现在研发的基本就围绕这 四个靶点 我称之为—— “代谢四小龙”——既各司其职，又能排列组合互相配合。 你就说，这么有意思的靶点，当初谁想到的呢。抛开庞大的市场规模不谈，就这排列组合，就值得越来越多企业布局代谢领域了。下一篇起，将按靶点专篇展开，并附该靶点的全球管线表。附：GLP-1现有主要药物表（附带碎碎念）表 1｜已上市的 GLP-1/相关类药物（代表性）
药物中文名（英文名）
靶点
主要特点（简述）
局限（简述）
碎碎念司美格鲁肽
（Semaglutide；Ozempic/Rybelsus/Wegovy）
GLP-1RA
周制剂与口服并存；体重与 HbA1c 双终点表现突出；肥胖长期管理适应症全球化推进。
早期 GI 反应；口服有给药要求。
单受体“标准样本”。替尔泊肽
（Tirzepatide；Mounjaro/Zepbound）
GLP-1/GIP 双受体
多项头对头显示强效减重/控糖；中国完成核心注册节点。
GI 反应需滴定管理。
代表性“双受体”。利拉鲁肽
（Liraglutide；Victoza/Saxenda）
GLP-1RA
证据成熟，含心血管结局数据；Saxenda 为肥胖适应症。
需每日注射；减重幅度有限。
经典基座。度拉糖肽
（Dulaglutide；Trulicity）
GLP-1RA
周制剂，控糖明确，安全性资料丰富。
减重幅度相对中等。
长期使用广泛。艾塞那肽
（Exenatide；Byetta/Bydureon）
GLP-1RA
早期代表品种，周制剂可选。
短效需每日多次，易产生抗体。
历史意义。贝那鲁肽
（Beinaglutide）
GLP-1RA
中国较早批准的短效 GLP-1RA。
需多次给药；应用范围有限。
名称常被误写为 “Benaglutide”。表 2｜临床开发中的代表性项目（节选）
药物中文名（英文名/代号）
受体/类型
研发阶段（全球/中国）
主要看点
碎碎念Mazdutide（IBI362）
GLP-1/GCG 双受体
中国：体重管理/控糖适应症相继落地
体重管理与代谢综合指标改善；真实世界待积累。
全球首个同类获批。Retatrutide（LY3437943）
三重（GLP-1/GIP/GCG）
III 期
极限体重下降潜力与长期安全窗。
多项试验在研。CagriSema（Semaglutide + Cagrilintide）
GLP-1 + Amylin
III 期/IIIa
68 周显著体重下降；不同合并症人群的效果待确认。
胃肠不适需管理。Orforglipron口服小分子 GLP-1
多项 III 期达主要终点
口服依从性、产能与成本的潜在优势。
关注长期安全与结局。HDM1002 / HDM1005（华东医药）
口服 GLP-1 / GLP-1/GIP（肽）
多项试验推进（含国内 III 期）
本土“口服化 + 多受体”探索。
以注册公示为准。HRS 系列（恒瑞医药，GLP-1/GIP/三重等）
双/三受体
国内 III 期（节选）
体重下降幅度接近国际同类；申报节奏受临床结果推动。
关注头对头数据。Ecnoglutide（思路迪 Sciwind）
GLP-1RA（周制剂）
国内 III 期积极读出
体重下降与国际标杆同量级。
安全性与可及性待观察。
说明：阶段/状态以最近公开资料为准；不同项目的适应症与入组人群差异较大，横向比较需谨慎。
版权说明：本文基于公开资料整理，供行业交流，不构成投资或医疗建议。转载请注明出处。反馈与更正：如发现事实性错误或需要补充的最新进展，欢迎留言或私信提交，我将在下一次更新中标注更正。
## 参考资料（节选）1. Wilding JPH, Batterham RL, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2021;384:989-1002. 2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med*. 2022;387:205-216. 3. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). *N Engl J Med*. 2021;385:503-515. 4. Coskun T, et al. Mechanisms of Glucagon and GLP-1 Co-agonism. *Cell Metab*. 2022;34:1-17. 5. Ludvik B, et al. Retatrutide (Triple GIP/GLP-1/Glucagon Receptor Agonist) in Obesity: Phase 2 Trial. *N Engl J Med*. 2023;389:2115-2128. 6. Lau DCW, et al. Cagrilintide plus Semaglutide for Weight Management: 68-Week Data. *N Engl J Med*. 2024/2025 在线发表7. Rosenstock J, et al. Oral Small-Molecule GLP-1 Receptor Agonists: Emerging Evidence. *Lancet Diabetes Endocrinol*. 2024;12 8. 中国国家药监局与公开注册库（ClinicalTrials.gov、ChiCTR）项目页面 9. 企业管线与新闻稿（诺和诺德、礼来、信达生物、华东医药、恒瑞医药、思路迪等；检索至 2025-10-22）
临床3期临床2期临床结果ASH会议
2025-10-10
·同写意
当一家制药巨头以其“钞能力”在市场上掀起风浪时，外界常常将其简单解读为一场资本的狂欢。然而，10月9日，诺和诺德宣布以高达52亿美元的价格收购Akero Therapeutics的交易，远非一次简单的资产扩充。
凭借GLP-1药物的惊人成功，诺和诺德登上了全球药企的市值之巅。但光环之下，潜藏着巨大的隐忧，单一赛道的内卷与增长天花板正在逼近。
这片被诺和诺德选中的新大陆，正是素有“制药业珠穆朗玛峰”之称的MASH（非酒精性脂肪性肝炎）领域。这里埋葬过无数巨头的雄心与数十亿美元的研发投入，至今仍是有效疗法稀缺。
而Akero，这家手握FGF21类似物（EFX）的明星公司，以其临床数据中展现出的逆转肝纤维化的巨大潜力，成为了诺和诺德眼中最理想的“登陆舰”。
TONACEA
01
豪掷千金
“这不仅仅是一次收购，而是我们构建代谢疾病领导地位的战略必需。”诺和诺德首席执行官Mike Doustdar在收购公告中道破这笔交易的本质。
根据协议条款，Akero股东将在交易完成时每股获得54.00美元现金，并获得一个不可转让的或有价值权（CVR），每个CVR将在Akero的核心药物efruxifermin（EFX）于2031年6月30日前获得FDA批准用于治疗由MASH引起的代偿期肝硬化后，赋予持有人每股6.00美元的额外现金支付权。
在资本市场趋冷的当下，这笔交易总价较Akero过去30日均价溢价仍高达32%，主要通过债务融资的交易预计将使诺和诺德2025年自由现金流减少约40亿美元。
交易围绕标的EFX，它的故事始于对FGF21这一关键代谢调节激素的深入探索。FGF21天然具有调节能量平衡、葡萄糖稳态和脂质代谢的能力，但其较短的半衰期限制了临床应用。Akero的科学家们决心攻克这一难题。
经过精心设计，研究团队创造性地将FGF21分子与免疫球蛋白Fc结构域融合，形成了Fc-FGF21融合蛋白。这一巧妙的结构改造使EFX的半衰期显著延长，实现了每周一次皮下给药的便利性，大大提升了患者的用药依从性。
EFX的作用机制犹如一把精准的代谢调节钥匙，通过激活FGF受体1c与β-Klotho共受体复合物，启动下游信号通路，直接作用于肝脏代谢。这种多靶点作用机制使其能够同时实现减少肝脏脂肪、改善胰岛素敏感性、逆转肝细胞损伤和直接抗纤维化等多重效果。
在临床开发道路上，EFX展现出了令人振奋的数据。针对不同疾病分期的II期临床试验HARMONY（F2-F3期患者）和SYMMETRY（F4代偿期肝硬化患者）均取得了突破性结果。
数据显示，在96周时，50 mg组有49%的患者实现了肝纤维化改善至少1期且MASH没有恶化，显著高于安慰剂组的19%。50 mg组中57%的患者实现MASH完全缓解，且没有纤维化恶化，而安慰剂组仅为24%。
同时，在更棘手的F4期患者中，仍有29%获得肝纤维化逆转（安慰剂组11%）。更值得关注的是，在基线和第96周进行活检的患者中，EFX 50mg组有39%实现肝硬化逆转且MASH没有恶化，而安慰剂组仅为15%。
这些数据使EFX成为目前唯一在II期试验中显示F4患者肝纤维化显著逆转的疗法，为晚期MASH患者带来了前所未有的希望。
TONACEA
02
下一个必争之地
不可否认，MASH正成为制药巨头眼中的“香饽饽”。
通俗来说，MASH就是严重版的脂肪肝。当肝脏中的脂肪堆积引发炎症和纤维化，最终可能走向肝硬化甚至肝癌。全球有超过2.65亿人受此病困扰，其中，中国患者人数就从2019年的3710万增长至2024年的4400万。
值得一提的是，MASH与诺和诺德的核心业务高度协同。数据显示，超过40%的MASH患者患有2型糖尿病，超过80%的MASH患者超重或肥胖。
2024年3月，首个获得FDA批准用于治疗MASH的药物resmetirom（Rezdiffra）面世，来自Madrigal，适应症为联合饮食和运动治疗成人非肝硬化MASH伴有中重度肝纤维化（F2-F3期）患者。
上市首年，Rezdiffra便收获3.17亿美元的销售额，今年第二季度销售额达到2.13亿美元。Madrigal预计，2025年全年销售额或将突破8亿美元。
8月，FDA批准第二款MASH治疗药物司美格鲁肽。这款产品来自本次交易中的另一主角——诺和诺德，用于治疗非肝硬化MASH伴中重度肝纤维化（F2-F3期）的成人患者。
不难看出，这两款药物聚焦早期患者，留下了巨大的市场空白。据沙利文预测，2030年MASH的全球药物市场有望达到322亿美元。MASH赛道的竞争格局，正随着大药厂的纷纷入局而迅速升温。
在EFX之外，罗氏在9月底刚以35亿美元收购89bio，获得其III期FGF21类似物pegozafermin；辉瑞的ervogastat和clesacostat组合已进入II期临床；礼来的FGF21类似物也在快速推进。这还不包括勃林格殷格翰与Zealand Pharma的合作项目，以及阿斯利康通过收购Cymabay获得的新资产。
各家企业采取了不同的科学路径，除了EFX代表的FGF21通路外，还有主要靶向肝脏能量代谢的THR-β激动剂（如Resmetirom），以及同时影响糖脂代谢的PPAR激动剂。在这种科学路径的多样性覆盖下，未来MASH治疗可能走向个性化精准治疗的时代。
TONACEA
03
诺和诺德的战略雄心
如果说GLP-1药物是诺和诺德登顶的利器，那么如今的代谢疾病大生态布局，则是其巩固王座的深谋远虑。还有一个不容忽视的现实是，司美格鲁肽的专利保护期正在缩短。这款“明星药物”为诺和诺德带来了前所未有的收入和市值，但专利悬崖的倒计时已经开始。
面对这一挑战，诺和诺德的选择是在现有核心产品仍在创造巨额现金流时，果断投入重金构建下一代产品组合。EFX正是这一战略的关键落子，它不仅能够单独使用，更有可能与诺和诺德的其他代谢产品形成组合疗法，创造新的治疗标准。
早期研究显示，EFX与GLP-1药物的联用可能产生“1+1>2”的协同效应，GLP-1调节食欲和血糖，FGF21直接改善肝脏代谢，共同构建全方位的代谢调节。
可以说，EFX的加入填补了诺和诺德在MASH领域的关键空白。在减重领域，除了现有的司美格鲁肽，新一代的CagriSema（司美格鲁肽+卡格列肽）已进入III期临床，口服小分子GLP-1受体激动剂也在快速推进。在糖尿病领域，胰岛素周制剂、GIP/GLP-1/胰高血糖素三受体激动剂等创新疗法构建了多层次的产品矩阵。
代谢领域之外，在技术平台拓展方面，诺和诺德不仅深耕蛋白质药物领域，还通过合作开发进入小分子领域。与阿里健康、腾讯健康等互联网医疗平台的合作，帮助诺和诺德直接触达患者，积累真实世界数据，反过来促进研发创新。
在代谢疾病治疗的新时代，单一药物的成功已不足以保证持续领先。构建涵盖多疾病领域、多治疗靶点的完整生态，才是制药企业的终极护城河。诺和诺德此次并购之举宣告，它不仅要当减肥药之王，更要成为整个代谢疾病领域的终极解决方案提供者。
参考文章：
1、https://mp.weixin.qq.com/s/Ir8gkLT5LGiHkym1iTvVRw
2、https://mp.weixin.qq.com/s/cIiu7b3GdPhj4I8uuE6P5A
并购申请上市临床2期临床成功
100 项与 Cagrilintide 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病 | 临床3期 | 美国 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 中国 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 日本 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 阿根廷 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 澳大利亚 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 巴西 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 保加利亚 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 加拿大 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 克罗地亚 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 捷克 | 2023-09-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | - | 3,417 | Cagrilintide-Semaglutide | 鏇糧製膚積鹹齋憲鏇淵(鹹鹽構簾壓鹽淵鬱衊繭) = Gastrointestinal adverse events (affecting 79.6% in the cagrilintide-semaglutide group and 39.9% in the placebo group), including nausea, vomiting, diarrhea, constipation, or abdominal pain, were mainly transient and mild-to-moderate in severity 窪獵艱觸鹽壓壓憲艱築 (餘鏇衊鹽蓋顧壓鏇艱選 ) | 积极 | 2025-08-14 | |
临床2期 | 92 | (Cagrilintide 2.4 mg + Semaglutide 2.4 mg) | 衊淵壓壓遞選範鏇鏇餘(遞鑰簾鑰憲獵鏇廠網範) = 網醖鏇壓窪遞糧製鏇齋 範製衊襯遞鬱鬱構簾遞 (膚襯壓艱壓艱範構構襯, 0.9) 更多 | - | 2023-07-27 | ||
(Semaglutide 2.4 mg + Placebo (Cagrilintide)) | 衊淵壓壓遞選範鏇鏇餘(遞鑰簾鑰憲獵鏇廠網範) = 齋膚膚壓顧願網淵淵廠 範製衊襯遞鬱鬱構簾遞 (膚襯壓艱壓艱範構構襯, 1.0) 更多 | ||||||
临床2期 | 706 | 衊鹽壓網膚艱鬱選簾鹽(膚醖觸鹹鬱齋築構繭衊) = 窪窪選遞鬱廠醖齋膚製 膚壓壓構衊顧繭齋簾遞 (窪窪積選遞襯觸選構齋, 5.6) 更多 | - | 2023-07-18 | |||
临床2期 | 92 | 構夢餘鏇構餘鏇淵醖壓(遞艱製鹹鬱壓衊觸鏇鑰): estimated treatment difference = -20.2 (95% CI, -39.8 ~ -0.7), P-Value = 0.04 | - | 2023-06-23 | |||
临床1期 | - | 96 | 築淵遞鹹餘夢糧鹽網製(獵糧願壓鬱餘範壓醖淵) = 鹹積糧鹽積廠壓壓糧觸 壓製窪繭醖築艱獵積鑰 (壓餘艱觸製鏇鹽衊襯窪 ) 更多 | - | 2021-04-22 | ||
築淵遞鹹餘夢糧鹽網製(獵糧願壓鬱餘範壓醖淵) = 願壓膚壓觸遞鬱鬱醖繭 壓製窪繭醖築艱獵積鑰 (壓餘艱觸製鏇鹽衊襯窪 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用